Release Summary

In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64% in Immunocompromised Subjects

Merck